Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

New Technology Add-on Payment: Impact on CAR T-cell Therapy Reimbursement

Oncology Practice Insider

On August 2, the Centers for Medicare and Medicaid (CMS) released the Hospital Inpatient Prospective Payment System final rule for fiscal year 2020. The rule finalizes changes that will affect all U.S. hospitals, including:

  • New Technology Add-on Payments, which includes CAR T-cell therapy;
  • Updates to the calculation and application of the wage index; and
  • A continuous 90-day reporting period for Promoting Interoperability programs.

Most of the changes will be effective October 1, 2019.  The final regulations will be published in the Federal Register on August 16, 2019.  CMS has also released a fact sheet highlighting key details. ASCO’s top takeaways for the cancer care community include provisions on a new technology add-on payment, changes to the wage index calculations, promoting interoperability programs, and updating the Hospital Inpatient Quality Reporting Program’s measure set and eCQM reporting requirements.

Read more about ASCO’s analysis in the IPPS final rule.